Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

Dusseldorf - Delayed Quote EUR

Cytokinetics Inc (KK3A.DU)

Compare

44.00

0.00

(0.00%)

As of 12:30:58 PM GMT+1. Market Open.

Cytokinetics, Incorporated (CYTK): the Most Oversold Pharma Stock to Buy According to Analysts

We recently published a list of the 10 Oversold Pharma Stocks to Buy According to Analysts. In this article, we are going to take a look at where Cytokinetics, Incorporated (NASDAQ:CYTK) stands against the other oversold pharma stocks to buy according to analysts. On February 20, Emily Field, Head of European Pharma Research at Barclays, […]

Insider Monkey 2 days ago

CYTK
Cytokinetics, Incorporated (CYTK): One of the Most Oversold Healthcare Stocks to Buy Now

We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a look at where Cytokinetics, Incorporated (NASDAQ:CYTK) stands against other most oversold healthcare stocks to buy now. Are Healthcare Costs Rising in the US? Healthcare costs and spending have been rising in […]

Insider Monkey 5 days ago

CYTK
Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 5 days ago

CYTK

RYTM
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on February 14, 2025 it granted stock options to purchase an aggregate of 23,337 shares of common stock and 15,153 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 6 employees, whose employment commenced in February 2025, as a material inducement to their employment. The RSUs will vest over 3 years, with 40% of the RSUs vesting

GlobeNewswire 6 days ago

CYTK
Cytokinetics to Announce Fourth Quarter Results on February 27, 2025

SOUTH SAN FRANCISCO, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on February 27, 2025 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company’s outlook for the future. The conference call will be simultaneously webcast and can be accessed from the

GlobeNewswire 12 days ago

CYTK
Cytokinetics Names Robert E. Landry to Board of Directors

Appointment Deepens Financial and Operational Expertise of Boardas Company Approaches Potential Commercialization SOUTH SAN FRANCISCO, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the appointment of Robert E. Landry to its Board of Directors. Mr. Landry brings over three decades of financial and operational expertise in the pharmaceutical industry, most recently having served as the Chief Financial Officer at Regeneron Pharmaceuticals Inc. f

GlobeNewswire 15 days ago

CYTK
Why Cytokinetics, Incorporated (CYTK) Is Among the Best Healthcare Stocks To Buy According to Analysts

We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to take a look at where Cytokinetics, Incorporated (NASDAQ:CYTK) stands against the other healthcare stocks. McKinsey reported that, since 2019, the US healthcare industry witnessed significant financial pressure. This is evidenced by the fact that industry […]

Insider Monkey 17 days ago

CYTK
Cytokinetics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

SOUTH SAN FRANCISCO, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12, 2025 at 4:40 PM Eastern Time. Interested parties may access the live webcast of the fireside chat by visiting the Investors & Media section of the Cytokinetics website at

GlobeNewswire 20 days ago

CYTK
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics

Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics are part of the Zacks top Analyst Blog.

Zacks 26 days ago

BIIB

SAGE

AKRO
Cytokinetics Announces Recipients of Its Seventh Annual Communications Grant Program

Total of $100,000 Awarded to Five Patient Advocacy Organizationsto Support Communications and Community Outreach SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the recipients of its seventh annual Communications Grant Program, intended to support increased communications, awareness building and community engagement. Five grants in the amount of $20,000 each were awarded this year to patient advocacy organizations serving t

GlobeNewswire 27 days ago

CYTK
Biotech Stock Roundup: SAGE Up on Declining BIIB's Offer, CYTK, AKRO Up on Updates

SAGE and AKRO are up this week on regulatory and pipeline updates.

Zacks 27 days ago

SAGE

BIIB

CYTK
What Are Analysts Talking About Cytokinetics (CYTK)?

We recently published a list of 10 Stocks That Analysts Are Talking About. In this article, we are going to take a look at where Cytokinetics, Incorporated (NASDAQ:CYTK) stands against other stocks that analysts are talking about. Like any other informed investor, we are always on the hunt for stocks that analysts are talking about. […]

Insider Monkey 29 days ago

CYTK
CYTK Stock Rises as Enrollment Begins in Phase II Heart Failure Study

Cytokinetics stock up as the company initiates patient enrollment in its mid-stage study of pipeline candidate, CK-586, for treating heart failure patients.

Zacks last month

CYTK
Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst

Stifel initiated coverage on Cytokinetics Incorporated (NASDAQ:CYTK), noting the company’s catalyst rich one to two years. The M&A speculation ramped up in early 2024 after the company released SEQUOIA-HCM Phase 3 trial data of aficamten in December 2023. However, last year, Novartis AG (NYSE:NVS) decided to step back from pursuing the Cytokinetics deal. Amgen Inc (NASDAQ:AMGN), AstraZeneca Plc (NASDAQ:AZN), and Johnson & Johnson (NYSE:JNJ) also all popped up as potential suitors, though the sto

Benzinga last month

CYTK
Cytokinetics Announces Start of AMBER-HFpEF, a Phase 2 Clinical Trial of CK-586 in Patients With Symptomatic Heart Failure With Preserved Ejection Fraction

SOUTH SAN FRANCISCO, Calif., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that AMBER-HFpEF (Assessment of CK-586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF) is open to enrollment. AMBER-HFpEF is a Phase 2 randomized, placebo-controlled, double-blind, multi-center, dose-finding clinical trial of CK-4021586 (CK-586) in patients with symptomatic heart failure with preserved ejection fraction (HFpEF) with left vent

GlobeNewswire last month

CYTK
Cytokinetics Announces 2025 Corporate Milestones and Vision 2030

PDUFA Target Action Date for Aficamten Set for September 26, 2025;Commercial Launch Preparations Underway for First Potential Approval Five-Year Aspirations Outline Corporate Strategies to Becoming Leading Muscle Biology Specialty Biopharma Company SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq: CYTK) today provided guidance for corporate milestones expected to occur in 2025 and outlined its aspirational Vision 2030, five-year strategic objectives desig

GlobeNewswire last month

CYTK
Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 9:00 AM Pacific Time in the Borgia Room of the Westin St. Francis Hotel in San Francisco, CA. Interested parties may access the live webcast of the presentation by visiting the Investors & Media section of the C

GlobeNewswire last month

CYTK
Cytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy

SOUTH SAN FRANCISCO, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for aficamten, a next-in-class cardiac myosin inhibitor, for the treatment of obstructive hypertrophic cardiomyopathy (HCM). The MAA will now be reviewed by the Committee for Medicinal Products for Human Use (CHMP). “With regulatory filings for aficamten already under review in

GlobeNewswire 2 months ago

CYTK
Why Cytokinetics Stock Was a Nearly 5% Winner Today

This is a drug targeting heart disease hypertrophic cardiomyopathy (HCM) that was developed by Cytokinetics. Cytokinetics originally sold those rights to Corxel in 2020. Additionally, it can reap royalties on future sales of the drug in Greater China.

Motley Fool 2 months ago

CYTK

SNY
Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China

SOUTH SAN FRANCISCO, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Sanofi will acquire exclusive rights to develop and commercialize aficamten from Corxel Pharmaceuticals (CORXEL) for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) in Greater China. Aficamten is a next-in-class cardiac myosin inhibitor for the potential treatment of patients with HCM. In 2020, CORXEL (formerly Ji Xing) acq

GlobeNewswire 2 months ago

CYTK

Performance Overview

Return	KK3A.DU	S&P 500
YTD	-0.90%	+1.25%
1-Year	-39.31%	+17.47%
3-Year	+42.86%	+35.82%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Cytokinetics Inc (KK3A.DU)

Cytokinetics, Incorporated (CYTK): the Most Oversold Pharma Stock to Buy According to Analysts

Cytokinetics, Incorporated (CYTK): One of the Most Oversold Healthcare Stocks to Buy Now

Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cytokinetics to Announce Fourth Quarter Results on February 27, 2025

Cytokinetics Names Robert E. Landry to Board of Directors

Why Cytokinetics, Incorporated (CYTK) Is Among the Best Healthcare Stocks To Buy According to Analysts

Cytokinetics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics

Cytokinetics Announces Recipients of Its Seventh Annual Communications Grant Program

Biotech Stock Roundup: SAGE Up on Declining BIIB's Offer, CYTK, AKRO Up on Updates

What Are Analysts Talking About Cytokinetics (CYTK)?

CYTK Stock Rises as Enrollment Begins in Phase II Heart Failure Study

Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst

Cytokinetics Announces Start of AMBER-HFpEF, a Phase 2 Clinical Trial of CK-586 in Patients With Symptomatic Heart Failure With Preserved Ejection Fraction

Cytokinetics Announces 2025 Corporate Milestones and Vision 2030

Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Cytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy

Why Cytokinetics Stock Was a Nearly 5% Winner Today

Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China

Performance Overview